MLND - Millendo Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart

Millendo Therapeutics's activity chart (see below) currently has 14 price targets and 11 ratings on display.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 50% of the time, taking 122.78 days on average.

Most recent stock forecast was given by from LADENBURG on 06-Jan-2021. First documented stock forecast 12-Dec-2018.

Best performing analysts who are covering MLND - Millendo Therapeutics:

Laura Chico Joel Beatty Jay Olson Matthew Kaplan Joseph Schwartz

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 07-Apr-2020

$5

5 years 10 months 15 days ago
(06-Jan-2021)

2/2 (100%)

$-21.85 (-81.38%)

592

Buy Since 12-Dec-2018

$30

$360

5 years 10 months 15 days ago
(05-Jan-2021)

1/2 (50%)

$5.55 (22.70%)

20

Buy Since 11-Mar-2020

$25

6 years 7 months 15 days ago
(06-Apr-2020)

1/1 (100%)

$-73.7 (-74.67%)

26

Buy Since 07-Feb-2020

$20

$23

6 years 7 months 28 days ago
(24-Mar-2020)

2/2 (100%)

$-76.15 (-79.20%)

215

Buy Since 16-Jul-2019

$25

7 years 3 months 8 days ago
(13-Aug-2019)

2/2 (100%)

$-81.5 (-76.53%)

252

Show more analysts

Please expand the browser size to see the chart

What is MLND (Millendo Therapeutics) average time for price targets to be met?

On average it took 123 days for the stock forecasts to be reached, with an average price target met ratio of 50%.

Which analyst most recently updated their price target on MLND (Millendo Therapeutics)?

Which analyst has the lowest performance score on MLND (Millendo Therapeutics) with a proven track record?

JOSEPH SCHWARTZ

Which analyst has the most public recommendations on MLND (Millendo Therapeutics)?

has 0 price targets and 0 ratings on MLND

Which analyst is the currently most bullish on MLND (Millendo Therapeutics)?

Jay Olson with the highest potential upside of $371.71

Which analyst is the currently most reserved on MLND (Millendo Therapeutics)?

Matthew Kaplan with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?